Skip to Content

    Investors are betting big on ­Regeneron: Its market value has jumped by more than a fifth in 2017. Why? Sales of eye-­disease treatment Eylea are strong. The company’s expansive pipeline could continue to fuel steady growth. Regeneron has 11 experimental treatments in Phase II or Phase III clinical trials. One that could prove critical is REGN2810, a type of next-generation medicine currently in late-stage studies that harnesses the body’s immune system to fight cancer.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score2.5
    Sector
    Health Care
    Industry
    Pharmaceuticals
    CEO
    Leonard S. Schleifer
    Websitehttp://www.regeneron.com
    Employees5,400
    HQ Location
    Tarrytown, N.Y.
    Revenues ($M) (Past 12 Months)$5,236
    Profits ($M) (Past 12 Months)$1,155
    Market Value as of Oct. 9, 2017 ($M)$50,054